CASI Pharmaceuticals (NASDAQ: CASI)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.640 | -0.560 | 0.0800 | ||||
REV | 7.870M | 8.573M | 703.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of CASI Pharmaceuticals (NASDAQ: CASI) through any online brokerage.
Other companies in CASI Pharmaceuticals’s space includes: Cabaletta Bio (NASDAQ:CABA), Acurx Pharmaceuticals (NASDAQ:ACXP), Celyad Oncology (NASDAQ:CYAD), Larimar Therapeutics (NASDAQ:LRMR) and VistaGen Therapeutics (NASDAQ:VTGN).
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by HC Wainwright & Co. on Monday, August 15, 2022. The analyst firm set a price target for 12.00 expecting CASI to rise to within 12 months (a possible 276.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for CASI Pharmaceuticals (NASDAQ: CASI) is $3.19 last updated Today at August 18, 2022, 2:37 PM UTC.
There are no upcoming dividends for CASI Pharmaceuticals.
CASI Pharmaceuticals’s Q3 earnings are confirmed for Friday, November 11, 2022.
There is no upcoming split for CASI Pharmaceuticals.
CASI Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.